ReviewCancer prevention research (Philadelphia, Pa.)2010
Vaccine prevention of cancer: can endogenous antigens be targeted?
Review in Cancer prevention research (Philadelphia, Pa.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 26 citations in OpenAlex.
- Immunomodulatory role of vitamin D and emerging immunotherapies in hepatocellular carcinoma.Frontiers in nutrition · 2025Review
- A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma.Vaccines · 2023Review
- Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52.Human vaccines & immunotherapeutics · 2020Article
- Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Review
- Overexpressed oncogenic tumor-self antigens.Human vaccines & immunotherapeutics · 2014Review
- Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2013Article
- What is recent in pancreatic cancer immunotherapy?BioMed research international · 2013Review
- Future directions in cancer prevention.Nature reviews. Cancer · 2012Review
- Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Potential targets for pancreatic cancer immunotherapeutics.Immunotherapy · 2011Review
- Stimulation of anti-tumor immunity by photodynamic therapy.Expert review of clinical immunology · 2011Review
Corrections and comments
- Comment on
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
This perspective on the report by Beatty et al. in this issue of the journal (beginning on page 438) discusses the prevention of cancer through vaccination strategies that target antigens associated with tumor promotion and progression. Such approaches were first developed for treating cancer. We address cancer vaccination in the context of a mouse model of inflammatory bowel disease expressing MUC1, an epithelial mucin aberrantly expressed during chronic inflammation and in colorectal carcinogenesis, and in a broader context that includes the potential of targeting the tumor microenvironment for immunoprevention in humans. Obstacles in developing effective cancer vaccines, including antigen selection, immunoediting, and tumor-mediated immunosuppression, are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.